Business Wire

Leblon Delienne Joins LEXON at BOW to Expand Its Global Reach

8.9.2026 14:36:00 CEST | Business Wire | Press Release

Share

BOW (Brands of Wonder), the international brand group behind French design brand LEXON, today announced the acquisition of Leblon Delienne, the French sculpture atelier known for transforming pop culture icons into collectible art and design objects. The move pairs the atelier’s distinctive French craftsmanship and licensed collections with BOW’s international reach and digital expertise.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908641342/en/

Leblon Delienne Joins LEXON at BOW

Juliette de Blegiers, who acquired the company in 2018, will remain a minority shareholder in Leblon Delienne and continue working alongside BOW founder Boris Brault and the atelier’s teams.

For more than 40 years, Leblon Delienne has brought iconic characters to life through sculptures, figurines, furniture, and art and design objects, primarily in limited, numbered editions. Its licensed collections feature characters from Disney, Warner Bros., Peanuts, Playmobil, and Sanrio. The atelier also collaborates with artists, designers, interior designers, and luxury brands on exceptional custom commissions.

Its artisans craft sculptures at the atelier in Neufchâtel-en-Bray, Normandy. Leblon Delienne holds France’s Entreprise du Patrimoine Vivant (EPV, or “Living Heritage Company”) designation, an official distinction overseen by the French Ministry of the Economy and awarded to businesses with rare and exceptional know-how.

“Leblon Delienne is a truly distinctive atelier, transforming universally recognized characters into objects of desire,” said Boris Brault, founder and president of BOW. “It brings together everything that inspires me: history, emotion, craftsmanship, and a vision at the intersection of art, design, and pop culture.

With the global collectibles market flourishing, driven by a growing adult audience, Leblon Delienne and BOW are a natural creative and strategic fit. This marks a new step in our ambition to build a group of complementary design and art brands for the home, each with its own distinctive identity. Through LEXON, we have developed recognized expertise in creating licensed collections and collaborations with renowned partners around everyday design objects. With Leblon Delienne, we are now extending that approach to collectible art objects and strengthening our licensing portfolio.

Our aim is not to change Leblon Delienne, but to preserve its soul and give it the resources to go further: developing new collections, creating compelling collaborations, accelerating its digital growth, and expanding its international reach. I am especially pleased that Juliette will remain by my side as we begin this new chapter with our teams.”

Since joining BOW in 2018, LEXON has grown its global product sales nearly fivefold. International markets now account for 80% of its business, and the United States is its largest e-commerce market. LEXON has earned more than 250 international design awards and is sold in 90 countries through more than 9,000 retail locations, selling millions of products each year.

LEXON’s Balloon Dog collaboration with Jeff Koons, imagined with The Broad in Los Angeles, illustrates that combination of creative ambition and global reach. Its first edition attracted thousands of collectors worldwide in less than a year.

Leblon Delienne’s creative collaborators include Jean-Charles de Castelbajac, Eugeni Quitllet, and José Lévy. Both Quitllet and Lévy have also designed for LEXON, reflecting the two brands’ shared interest in design, emotional connection, and fresh interpretations of familiar objects and cultural icons.

BOW will support Leblon Delienne with its digital platforms and expertise in selling art and collectibles online, bringing its creations to new audiences and deepening relationships with collectors.

The group plans to develop new art licensing partnerships and exclusive sculptures while expanding international distribution. The ambition is to make Leblon Delienne a destination for collectors and a leading global name in collectible sculpture. Its Normandy atelier, artisans, and teams will remain at the heart of its creative work.

“Since 2018, we have worked with our teams to preserve and pass on our atelier’s craftsmanship while giving our creations a distinctly contemporary voice,” said Juliette de Blegiers, Chief Brands & Collaborations Officer at BOW. “We have maintained our expertise in the classic comic-book figurines that made Leblon Delienne’s name in the 1980s, while creating new collectible objects that reflect today’s culture.

What connects us with BOW is a shared commitment to artistic creation and to making timeless, increasingly sought-after objects. Leblon Delienne has enormous potential. The group will bring a product-focused approach, digital capabilities, and global distribution that complement our own strengths. I am proud of this partnership, which allows us to continue our brand’s story by drawing on each other’s strengths and a shared ambition.

I am also delighted to continue this journey alongside Boris Brault and write this next chapter together.”

ABOUT LEBLON DELIENNE
Founded in 1985, Leblon Delienne is a French sculpture atelier that reinterprets pop culture icons through figurines, sculptures, furniture, and design objects. Recognized with France’s Living Heritage Company designation, the atelier designs its collections in Neufchâtel-en-Bray, Normandy, France.
www.leblon-delienne.com

ABOUT BOW
Founded by Boris Brault, BOW (Brands of Wonder) is an entrepreneur-led international group that develops brands at the intersection of design, art, innovation, and emotional connection. Its brands include French design brand LEXON. The group combines expertise in product development, international distribution, and e-commerce.
www.group-bow.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260908641342/en/

Contacts

Media Contact: Sarah Brault – s.brault@group-bow.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye